![Loading Events](https://lifescievents.com/wp-content/plugins/the-events-calendar/src/resources/images/tribe-loading.gif)
Immunovant to Announce New Indications for Batoclimab
![Immunovant banner Immunovant banner](https://lifescievents.com/wp-content/uploads/2022/08/Immunovant-banner.png)
DATE: | September 7, 2022 |
---|---|
TIME: | 8:00 AM EDT |
LOCATION: | N/A |
About The Event
Immunovant to host an investor webcast to announce two new indications for their investigational product candidate, batoclimab (IMVT-1401). The event will feature prepared remarks by company management and external key opinion leaders in the autoimmune disease space.
Batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).
A live question and answer session with Immunovant management will follow.